Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical OutcomeYoon-Jae Cho, Scott L. Pomeroy|Journal of Clinical Oncology|2010Cited by 716
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in MedulloblastomaNataliya Zhukova, Rebecca M. Hill, David Jones et al.|Journal of Clinical Oncology|2013Cited by 488
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumorsSamuel Cheshier, Siddhartha S. Mitra, Abdullah H. Feroze et al.|Science Translational Medicine|2017Cited by 427
Clonal selection drives genetic divergence of metastatic medulloblastomaXiaochong Wu, Michael D. Taylor, Paul A. Northcott et al.|Nature|2012Cited by 412
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysisVijay Ramaswamy, Michael D. Taylor, Marc Remke et al.|The Lancet Oncology|2013Cited by 404